Home Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation
 

Keywords :   


Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

2014-06-26 18:42:26| Biotech - Topix.net

Agenus Inc. , an immuno-oncology company developing a portfolio of checkpoint modulators , heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 .

Tags: shows significant generated reduction

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
More »